PubMed Health⌕ Search

PubMed · 6545739

Classification of mitral valve prolapse.

Abstract

The scope of diagnosing mitral valve prolapse (MVP) has been enlarged by the earlier reported real-time B-scan criteria of small or "localised MVP". This form is believed to be the precursor of the overt MVP which is then readily diagnosed by angiocardiography and 1- and 2-dimensional echocardiography (1- and 2-dE). Rheumatic heart disease (RHD) is believed to be recognisable much earlier as well, by the previously reported 1- and 2-dE features of "early commissural fusion" (ECF). 30 patients in whom overt or localised MVP were diagnosed previously were reviewed for overt or early signs of ECF. In all patients early or overt echo features of RHD could be visualised. Thus RHD may be the most important cause of acquired MVP, even though it is rarely considered in recent classifications. It is proposed that RHD is perhaps the unifying link for all forms of MVP. GOTTLIEB and CHUNG were asking for such a unifying link "since the present classification is dubious at best. It offers nothing to use clinically and may actually be in error, since the primary form may be a less overt expression of the secondary form." It is proposed that mostly unrecognised rheumatic fever may be the underlying first lesion leading to the various different mechanisms described for MVP. If this can be confirmed, a new approach to primary prevention of rheumatic fever and its subclinical forms may be necessary. There is also some evidence to suggest that RHD may be the early and unrecognised microlesion in the coronary arteries as well and thus the important early factor in the development of macroscopic coronary artery disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Gehrke. 1983. Classification of mitral valve prolapse.. https://pubmed.ncbi.nlm.nih.gov/6545739/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗